Bionxt working on melt-in-your-mouth cladribine product

Executive Summary

• Bionxt Solutions Inc. is advancing the development of BNT23001, a next-generation "melt-in-your-mouth" oral dissolvable film (ODF) formulation of cladribine, designed to address dysphagia (swallowing difficulties) in multiple sclerosis (MS) patients.
• The proprietary sublingual delivery system aims to eliminate the need for swallowing, thereby improving treatment adherence, safety, and quality of life for patients who struggle with traditional tablet-based cladribine therapies.
• The company highlights a significant market opportunity, noting that the global cladribine market was valued at $1.2 billion in 2023 and is projected to reach $2.5 billion by 2032, driven by rising MS prevalence and demand for innovative drug delivery formats.

Key Details

• Product Technology: BNT23001 utilizes Bionxt’s proprietary oral dissolvable film (ODF) system, engineered for rapid sublingual absorption under the tongue.
• Target Indication: Multiple Sclerosis (MS), specifically targeting patients with dysphagia.
• Clinical Context: A 2023 meta-analysis of over 10,800 MS patients indicated that approximately 45% experience dysphagia, with instrumental assessments revealing abnormalities in over 50% of patients.
• Market Data:
  • Merck KGaA’s Mavenclad (cladribine tablets) generated $1.28 billion in global sales in 2024.
  • Mavenclad generated over $950 million in the first three quarters of 2025.
  • Global cladribine market valuation: $1.2 billion (2023) to $2.5 billion (2032), representing an 8.5% CAGR.
  • Oral transmucosal drug delivery market expected to grow from $45.8 billion (2025) to $96.8 billion (2033).
• Regulatory/Commercial Status: Bionxt is advancing regulatory approvals and commercialization efforts, primarily focused on European markets.
• Company Listing: Canadian Securities Exchange (BNXT), OTC Markets (BNXTF), and Germany (WKN: A3D1K3).

Notable Quotes

• "Taking a tablet should not be a barrier to treatment," said Hugh Rogers, chief executive officer of Bionxt Solutions. "Our melt-in-your-mouth cladribine film is designed specifically for MS patients who struggle to swallow pills. We are addressing a meaningful unmet need by making an important therapy easier, safer and more accessible in everyday life."